Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the initiation of the ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

Boston Scientific Corporation today announced positive 12-month primary endpoint results from the second phase of the ...

The upper pulmonary veins (PVs) are responsible for the majority of atrial fibrillation (AF) triggering foci, whereas the inferior PVs are more difficult to ablate and prone to postablation ostial ...

Boston Scientific (BSX) announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial ...

These foci are commonly in the superior pulmonary veins; this is an important factor in the electrophysiologic approach to atrial fibrillation, known as pulmonary vein isolation. Less commonly ...

Two state-of-the-art new technologies for transcatheter tricuspid valve replacements is expanding advanced heart care with ...

Pulmonary embolism (PE) is a significant cause of morbidity and mortality, particularly in patients classified as acute, ...

For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed ...

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated ...

The following is a summary of “Right atrial reservoir strain as an early predictor of pulmonary hypertension development in ...